Clinical significance and role of up-regulation of SERPINA3 expression in endometrial cancer

doi:10.12998/wjcc.v7.i15.1996

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 7, Issue 15

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (4965)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Tables (1-2) series.

Item

Count

PDF

353

WORD

160

HTML

2533

Tables (1-2)

138

Sum=3184

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

667

Download

1114

Sum=1781

Aug 6, 2019 (publication date) through Apr 25, 2024

Times Cited of This Article

Times Cited (16)

Journal Information of This Article

Publication Name

World Journal of Clinical Cases

ISSN

2307-8960

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Observational Study

World J Clin Cases. Aug 6, 2019; 7(15): 1996-2002
Published online Aug 6, 2019. doi: 10.12998/wjcc.v7.i15.1996

Clinical significance and role of up-regulation of SERPINA3 expression in endometrial cancer

Mian-Li Zhou, Fang-Shan Chen, Hui Mao

Mian-Li Zhou, Fang-Shan Chen, Department of Gynecology and Obstetrics, Traditional Chinese Medicine Hospital Affiliated to Southwest Medical University, Luzhou 646000, Sichuan Province, China

Hui Mao, Department of Oncology, Traditional Chinese Medicine Hospital Affiliated to Southwest Medical University, Luzhou 646000, Sichuan Province, China

Author contributions: Zhou ML, Chen FS, and Mao H designed the study and wrote the manuscript.

Institutional review board statement: The study was approved by Hospital of Traditional Chinese Medicine Affiliated to Southwest Medical University on October 28, 2016 (Research ethics No. CHEC2016-111).

Informed consent statement: All subjects gave informed consent prior to study inclusion.

Conflict-of-interest statement: The authors have no conflicts of interest to disclose.

Data sharing statement: No additional data are available.

STROBE statement: The authors have read the STROBE Statement, and the manuscript was prepared and revised according to the STROBE Statement.

Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

Corresponding author: Hui Mao, MD, Professor, Department of Oncology, Traditional Chinese Medicine Hospital Affiliated to Southwest Medical University, No. 182, Chunhui Road, Longmatan District, Luzhou 646000, Sichuan Province, China. 15196087724@163.com

Telephone: +86-830-2397165

Received: April 28, 2019
Peer-review started: May 7, 2019
First decision: May 30, 2019
Revised: June 19, 2019
Accepted: July 3, 2019
Article in press: July 3, 2019
Published online: August 6, 2019

ARTICLE HIGHLIGHTS

Research background

The expression profile of serpin peptidase inhibitor clade A member 3 (SERPINA3) in patients with endometrial cancer has rarely been studied. In the present study, we detected the protein levels of SERPINA3 in patients with endometrial cancer and the correlation between the expression of SERPINA3 and the prognosis for endometrial cancer. The result revealed that SERPINA3 expression was significantly up-regulated in endometrial cancer and was closely correlated with pathological grade, clinical stage, vascular invasion, and lymph node metastasis. These findings indicated that SERPINA3 can be used as a prognostic biomarker for endometrial cancer and as one of the targets for bio-targeted therapy for endometrial cancer.

Research motivation

The results of the present study may provide insight into the application of SERPINA3 as a predictor of clinical outcomes and a potential therapeutic target for endometrial cancer.

Research objectives

The present study aimed to assess the significance of SERPINA3 levels in patients with endometrial cancer.

Research methods

The present study examined tissue samples which were available from patients with endometrial cancer and patients with normal endometrial tissues. Tissue microarrays were constructed and immunohistochemical staining was performed. The expression of SERPINA3 mRNA was detected by quantitative PCR. The data were analyzed with SPSS19.0 software.

Research results

We found that SERPINA3 expression was higher in endometrial cancer compared to normal tissues and up-regulated SERPINA3 was closely correlated with pathological grade, clinical stage, vascular invasion, and lymph node metastasis in endometrial cancer.

Research conclusions

Assessment of tumor vs normal tissues showed that the expression of SERPINA3 was up-regulated in endometrial cancer. The SERPINA3 protein level in endometrial cancer cells was associated with pathological grade, clinical stage, vascular invasion, and lymph node metastasis, rather than with the age range at which women experienced menopause. SERPINA3 has the potential to be used as a biomarker for prognosis and a specific target for targeted therapy in patients with endometrial carcinomas.

Research perspectives

Further studies are warranted to improve our understanding of the role of SERPINA3 in endometrial cancer.